Industry News
Melbourne's HealthLinx signs assay deal with Bruker
Melbourne-based health-management house HealthLinx has signed a collaboration agreement with US clinical proteomics company Bruker Daltonics to develop a multiplex, in vitro diagnostic (IVD) assay for ovarian cancer. [ + ]
Research network for fluorescence applications
A network that brings together over 60 leading Australian researchers who advance cutting-edge fluorescence technologies has been launched at Macquarie University.
[ + ]Ventracor implants first European patient
Sydney's Ventracor (ASX:VCR) has announced the first European implant of its VentrAssist device as part of its CE Mark Trial. [ + ]
Genesis flush after ArboGen stoush settles
Auckland-based biotech Genesis Research (ASX/NZSX:GEN) has received a valuable boost to its bottom line after an out-of-court settlement of its long-running dispute with former US ally, Delaware-based forestry biotech company ArboGen. [ + ]
Ambri back to the drawing board
Medical diagnostics company Ambri (ASX:ABI) is busy back at the drawing board developing a new chip biosensor after suspending the development of its SensiDX project. [ + ]
Academy elects 16 new members
Internationally renowned molecular geneticist Dr Robin Holliday is among 16 Australian scientists elected this month to the Australian Academy of Science. [ + ]
Liability clauses to be removed from CRC contract
The federal government is to remove a controversial liability clause from Commonwealth contracts with new Cooperative Research Centres (CRCs), education minister Brendan Nelson told delegates at last week's 2005 CRC Association Conference in Melbourne. [ + ]
In brief: Benitec, Probiomics, Progen, Avastra
Queensland Investment Corporation has ceased to be a substantial shareholder in Benitec (ASX:BLT), but millionaire Richard Pratt's Thorney Group has upped its holding in the company to 11.54 per cent. [ + ]
Acrux signs dermatology products deal
Specialty pharmaceutical company Acrux (ASX:ACR) has signed an agreement giving newly-formed San Francisco bay area company Napa Biosciences the rights to use Acrux's drug delivery technology in a number of dermatology products. [ + ]
Dye to pinpoint diseases
University of Toronto researchers have designed a chemical screening tool that will light up when dangerous pathogens and diseases in air, water and bodily fluids are present.
[ + ]Cornering cholera
A new treatment for the age-old scourge of cholera and perhaps a whole new type of antibiotic medicine may emerge from chemicals discovered in an Australian seaweed, new research results suggest.
[ + ]NZ budget boosts R&D
New Zealand's biotechnology industry has welcomed a "solid incremental improvement" in S&T funding in this week's NZ budget. [ + ]
Govt R&D investment continues to slip
The Federation of Australian Scientific and Technological Societies (FASTS) has warned that Commonwealth investment in research and development will drop below 0.6 per cent of gross domestic product as a result this month's federal budget. [ + ]
'Heavy-hearted' Smith steps down from Amrad
Pete Smith has resigned as CEO of Amrad (ASX:AML), along with chairman Bob Moses as chairman, following a board meeting yesterday. [ + ]
Living Cell Technologies finalises technology acquisition
Auckland-based cell therapy company Living Cell Technologies (ASX:LCT) will hold a general meeting next week to formally seal a deal under which it has acquired technology and IP worth US$90 million from with US cell-therapy company Theracyte. [ + ]
